09:55:52 EDT Sun 21 Apr 2024
Enter Symbol
or Name

Login ID:
Innocan Pharma Corp
Symbol INNO
Shares Issued 248,490,093
Close 2023-03-22 C$ 0.25
Market Cap C$ 62,122,523
Recent Sedar Documents

Innocan releases results of vaginal derma efficacy test

2023-03-23 09:22 ET - News Release

Ms. Iris Bincovich reports


Innocan Pharma Corp. has released the successful results of a controlled efficacy test regarding its vaginal derma product.

The results of the trial demonstrate that Innocan's product, which contains cannabinoids, phytoestrogens, hyaluronic acid and probiotics, effectively reduced the symptoms, and improved overall vaginal health.

The 56-day trial was conducted with a group of female volunteers experiencing symptoms of vaginal dryness, stinging, burning, infection and pain during urination.

The primary indication of the trial was a statistically significant alleviation of symptoms after 28 days of product use.

Furthermore, 94 per cent of the volunteers reported a reduction in vaginal dryness, 94 per cent indicated better sensation during intimate relationships and 91 per cent stated that the vaginal area became more elastic. Additionally, 93 per cent of the volunteers reported a reduction in discomfort during sports activity, 94 per cent felt immediate relief from vaginal itching, 93 per cent felt their skin was healthier and 97 per cent would recommend the product to others.

The product does not contain hormones or steroids, which are commonly used to treat similar symptoms and can have negative side effects. Innocan's use of cannabinoids and other natural ingredients offers a healthy alternative for women seeking relief from vaginal discomfort.

"We are thrilled with the results of this efficacy test and the positive impact our product had on the women who participated," said Iris Bincovich, chief executive officer of Innocan. "Our focus is on developing safe and effective products that can improve the quality of life for people in need, and we are proud to achieve such promising results with our vaginal derma product."

About Innocan Pharma Corp.

Innocan is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness. In the pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprising cannabinoids science to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) liposome platform technology (LPT) CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the central nervous system (CNS). In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted on-line sales.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.